Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. - Test2 - elhamkhani - TriplyDB

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

http://www.wikidata.org/entity/Q34393008

about

Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options New β-Lactamase Inhibitors in the Clinic Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections What's new in multidrug-resistant pathogens in the ICU?Targeting Antibiotic Resistance Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Polyphosphate Kinase Mediates Antibiotic Tolerance in Extraintestinal Pathogenic Escherichia coli PCN033 Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Natural product and natural product derived drugs in clinical trials.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.Antibiotics: from prehistory to the present day.Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.An update on emerging therapies for urinary tract infections.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.β-Lactams and β-Lactamase Inhibitors: An Overview.Emerging drugs for nosocomial pneumonia.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.Challenges and opportunities in the treatment of ventilator-associated pneumonia.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity.Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?

P2860

Q21146707-51270775-2632-4D7D-A4A6-A17976F1AA79 Q26747150-D274C819-1559-4E7D-8BC2-D0A8FB21ED1D Q26751255-C99624E5-EF94-41AB-9F0A-0647F028577B Q27001490-58AA7329-3A6A-4483-83E8-CFD0BE2A1E1C Q28071346-02381969-9D23-430C-90E4-9088A1382F70 Q28078130-5F0D869C-40D7-40B0-8272-FA2801244798 Q33617939-71A964B0-F2A0-45E3-9235-D49A3D9DCC27 Q33630591-5BB91F8D-5407-4598-B898-A59572F9A8C7 Q34688710-F08C2CF8-BF8D-443B-ADC2-1D0BF0E23FC8 Q36075893-0DADF064-A3D8-4847-8B18-F128247F725F Q36761826-E76B694F-CC24-4C4A-9575-0C66BA2D1193 Q36913948-D6B4D94C-B158-41EB-9D53-4D706006B3C8 Q37023118-15E7B50E-F889-44F7-B33B-BAA4E7C94BEF Q37119083-8B7C7E5A-8AAE-435C-BAB0-9524551DDA08 Q37358630-4B933CDF-DDB6-4E86-8E62-33450EFFC4E1 Q38222497-E0F7E3EA-5F04-4183-9C9E-CD79054A5301 Q38241417-EB77A16F-9EA1-4059-B63E-4B243276D87F Q38247457-C851B267-D756-4017-9A7D-D09E431C6124 Q38286351-2349814D-39DA-4E53-9C1D-D0B1AEC2CC1E Q38296151-03BC68FC-8ED5-491C-A7CA-1CB3D16C65F5 Q38384662-A6B4B7C9-9486-4680-B434-9C392009B817 Q38650049-8FFAACB6-41C8-4ACC-A13A-DB6C19483AFA Q38690748-A23063B0-7D9B-4147-B261-8E3CE8CFFBB1 Q38697988-1E561938-ACCE-4368-AACE-6AA5F8CF6271 Q38724754-281B56FC-A984-4F50-92CD-ABD5EBC391CC Q38740494-B46D0D60-62AA-4099-B43A-4BC0DF32C0B0 Q38751454-8FF26D3C-48C3-41D8-BDA3-054B4F2D5D0E Q38792841-4C45D67A-7052-4064-A7A9-5CEF49E8C884 Q38872130-8C1B016B-06AD-4F7C-A7E4-BB4FD008729F Q38872374-3688823C-1948-4F81-AA6F-640D9320B311 Q38878167-0A41A880-804E-45D8-B304-324F15FB51DE Q38934400-229353ED-AA27-4E49-8C28-F19F9AB00716 Q38988630-F190FE90-4A4B-4F05-AF47-01AE7BAC3008 Q39066154-7FED2F53-C91B-4189-9830-2B62686A7DC8 Q39597152-9AFC1CD4-C3CF-4955-935C-22543B6EDD4A Q39905753-4B493157-ECB7-4911-9734-454361483620 Q40052714-D25C108D-5B5D-4F4F-84B7-31A420848C8D Q40095692-EB71A686-622C-4EBB-B47E-34BD0A03B845 Q40187310-43C761E4-8A48-49A8-B013-BBF08E986803 Q40550507-2D0FB2B8-16D2-4BBF-94C3-C42DE98A26BA

P2860

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

http://www.wikidata.org/entity/Q34393008

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@ast

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@en

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@nl

type

label

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@ast

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@en

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@nl

prefLabel

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@ast

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@en

Ceftolozane/tazobactam: a nove ...... sistant gram-negative bacilli.

@nl

P1433

Q34393008-3526665E-D462-4D9A-8BB7-4343FD4CB8FE

P1476

Q34393008-BE2B99ED-1271-493C-907E-DEF5A30649FE

P2093

Q34393008-4D18D3B5-C50F-4F92-870D-D9A8B5F33905

Q34393008-546260AF-2D17-4EF7-BADD-CDF2D6FCF54F

Q34393008-66698FB3-3BCA-4739-AB79-14F88B83D38A

Q34393008-6B1C2444-3228-494C-8CED-BFAF297AB056

Q34393008-92FF4A3C-043D-44A9-BDFF-0D1084F15B78

Q34393008-A668B53C-11B8-40C6-9BE7-945F02E17E48

Q34393008-B932FECF-40E7-48FB-824E-12B113E5509F

Q34393008-BB1CEA61-C8F1-4E8E-A095-1DA18B0CDFC2

Q34393008-C6045EF6-386A-4594-81C3-A302326DBDA8

Q34393008-FBC0691D-BC82-40C2-BE74-A58CF5C0B705

P2860

Q34393008-04E4E1A7-F158-414B-B1E3-4DEC06EC3B78

Q34393008-0B18B8F8-A91D-42F6-B188-079DA42146B2

Q34393008-13B56AD0-AB0F-42B6-9950-38703CB458DC

Q34393008-156F43EE-2603-42B5-BC39-5B7F88800462

Q34393008-17B02250-EC93-4DEC-B5C0-2F19EA75FB66

Q34393008-20018D78-0EBC-4E71-A667-2A54C62A4AED

Q34393008-2A94D210-0165-4E09-B293-F53FB0AE015C

Q34393008-2FA8F844-7538-4975-A9A9-5F3213F9F627

Q34393008-34B4CDF7-39C3-475D-83FE-53AA31AA991D

Q34393008-3B0BEE2F-BB63-4A80-A081-F56462A972B4

P2888

Q34393008-C2A8BC17-2B98-4B1D-97BB-556B80E7C955

P304

Q34393008-7F9B7262-24DA-4EC4-A542-9E40F05D18B5

P31

Q34393008-54594D3C-B2BF-48CC-88F2-8242EC0FE446

P356

Q34393008-5826C1C3-4B05-48DD-881B-EEE35A5B6E7E

P433

Q34393008-F043999C-5E9E-41B0-8E31-FE94EDFAC802

P478

Q34393008-2944EA78-5608-4E6A-817F-9D047862926A

P50

Q34393008-0F1BCA01-AF28-4A7E-A3D2-47343309526D

Q34393008-2B246EFB-F690-41B9-9BBA-A1E562116528

Q34393008-EC80FEBF-7063-4B5F-BC1E-3E6680E93DF3

P577

Q34393008-2DD4B1D8-4AE2-4627-98B3-CDC56A4942C9

P6179

Q34393008-60ECE720-107D-4382-A7F6-67FDC5E8B2BD

P698

Q34393008-7BD7A262-569F-4833-A620-C7B6E6CEA2C6

P921

Q34393008-8AED6D4C-FD93-41D9-9CB6-3513C5CCE37D

Q34393008-E5ADB2BD-9BE9-4522-8DCE-6CEDD193BE85

P356

S40265-013-0168-2

P1433

P1476

Ceftolozane/tazobactam: a nove ...... esistant gram-negative bacilli

@en

P2093

Alfred S Gin

http://www.w3.org/2001/XMLSchema#string

Andrew Denisuik

http://www.w3.org/2001/XMLSchema#string

Andrew Walkty

http://www.w3.org/2001/XMLSchema#string

Daryl J Hoban

http://www.w3.org/2001/XMLSchema#string

Ethan Rubinstein

http://www.w3.org/2001/XMLSchema#string

Frank Schweizer

http://www.w3.org/2001/XMLSchema#string

Heather Adam

http://www.w3.org/2001/XMLSchema#string

James A Karlowsky

http://www.w3.org/2001/XMLSchema#string

Joseph P Lynch

http://www.w3.org/2001/XMLSchema#string

Phillip Chung

http://www.w3.org/2001/XMLSchema#string

P2860

Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action.

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

Three decades of beta-lactamase inhibitors

Pseudomonas aeruginosa: all roads lead to resistance

Penicillin-binding proteins and beta-lactam resistance

Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein.

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

Class A beta-lactamases--enzyme-inhibitor interactions and resistance.

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

P2888

s40265-013-0168-2

P304

31-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-013-0168-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Sheryl A. Zelenitsky

Philippe Lagacé-Wiens

George G Zhanel

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003597975

http://www.w3.org/2001/XMLSchema#string

P698

24352909

http://www.w3.org/2001/XMLSchema#string

P921

Gram-negative bacteria

multiple drug resistance